• Alnylam expanded its commercial partnership with GENESIS Pharma to cover Denmark, Finland, Norway, Sweden.
• Deal grants GENESIS rights to commercialize Alnylam RNAi therapeutics for serious cardiomyopathy conditions, rare genetic diseases across the expanded territory.
• Partnership began in 2019, covering 13 Southeast European markets; latest expansion extends Alnylam’s reach in partner and emerging markets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606100747BIZWIRE_USPR_____20260610_BW467298) on June 10, 2026, and is solely responsible for the information contained therein.